Primary Job Title CEO Primary Organization NOVOS
Location New York, New York, United States Regions Greater New York Area, East Coast, Northeastern US Gender Male
Website www.novoslabs.com LinkedIn View on LinkedIn X (Twitter) View on X
Chris Mirabile is Founder & CEO of NOVOS, and formerly a co-founder and CEO of the geosocial networking technology, Hotlist.
NOVOS is a consumer longevity biotech platform, focused on slowing down the biological pace of aging and improving healthspans and lifespans. With a team of longevity scientists and MDs out of Harvard Medical School,
MIT, and other esteemed institutions, NOVOS is the first company to simultaneously address the 12 biological mechanisms (causes) of aging with its OTC formulations. NOVOS also offers biological age tests, such as epigenetic tests, for customers to be able to track their aging process, and to ensure that their lifestyle changes are making material improvements.
NOVOS is a Public Benefit Corporation, providing science-backed information and resources to users across the world for free, in pursuit of its vision to contribute 1+ billion years of healthy life to humanity.
Mirabile, a graduate of New York University Stern School of Business, was the youngest entrant to win the NYU Stern Business Plan Competition, from which his first startup, geosocial networking platform Hotlist.com was launched.
After more than 700,000 nominations for 25 categories, Chris was a top five finalist in the category of Entrepreneur of The Year at the 2011 Consumer Electronics Show, as part of the 2010 Mashable Awards.
Mirabile's technology career began at age 15, when he worked as a Web Consultant to the Silicon Alley startup, InternetCash.com. In 2002, at the age of 18, Mirabile led international expansion efforts for a US-based industrial contracting firm, United States Rebar. The resulting Mumbai, India-based technology subsidiary was recently acquired by an international steel conglomerate.
Immediately prior to Hotlist, Mirabile worked in Private Equity at Putnam Lovell Investment Bank, and as a Consultant to hedge funds both on behalf of Morgan Stanley, as well as independently.
